Evidence map›Paper›PMID 40472843›Full record

ArticleStructure (London, England : 1993)2025

Biochemical analysis of PD-L1 ubiquitination by CRL3

Guojiao Xie, Lin Gao, Renee Lu, Linxia Tian, Tiantian Zheng, Xinning Li, Yongjun Dang, Philip A Cole, Xian Yu, Hanjie Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Structure (London, England : 1993), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ClonalLife science alliance · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guojiao XieBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Lin GaoBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Renee LuDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA.
Linxia TianBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Tiantian ZhengBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Xinning LiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Yongjun DangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Philip A ColeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA.
Xian YuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China. Electronic address: 303671@cqmu.edu.cn.
Hanjie JiangDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA; Institute of Medical Physiology, Chinese Institutes for Medical Research (CIMR), Beijing 100069, China; Capital Medical University, Beijing 100069, China. Electronic address: hjiang@cimrbj.ac.cn.
Zan ChenBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China. Electronic address: zanchen@cqmu.edu.cn.

Funding

Chemical Approaches to Protein PhosphorylationR01CA074305 · NCI · JOHNS HOPKINS UNIVERSITY · PI COLE, PHILIP A · 2002 to 2025
$8.0M
ENZYMATIC STUDIES ON PROTEIN TYROSINE KINASE CSKR29CA074305 · NCI · ROCKEFELLER UNIVERSITY · PI COLE, PHILIP A · 1997 to 2001
$188k
NCI NIH HHS R01 CA074305NCI NIH HHS R29 CA074305
6 · The paper itself

Abstract

As a key immune checkpoint ligand, PD-L1 is a critical target in cancer immunotherapy. While multiple E3 ubiquitin ligases including CRL3

Indexed as

B7-H1 AntigenNedd4 Ubiquitin Protein LigasesUbiquitin-Protein LigasesHEK293 CellsHumansPhosphorylationProtein BindingUbiquitinationB7-H1 AntigenCD274 protein, humanNedd4 protein, humanNedd4 Ubiquitin Protein LigasesUbiquitin-Protein LigasesARIH1Cullin RING ubiquitin ligasemembrane associationNEDD4 family ubiquitin ligasesPD-L1phosphorylationubiquitination

Identifiers

PMID40472843
PMCPMC12335357

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.